Menu
Search
|

Menu

Close
X

Glenmark Pharmaceuticals Ltd GLEN.BO (Bombay Stock Exchange)

521.80 INR
-7.75 (-1.46%)
As of Feb 16
chart
Previous Close 529.55
Open 526.10
Volume 56,265
3m Avg Volume 94,329
Today’s High 532.05
Today’s Low 520.40
52 Week High 957.50
52 Week Low 520.40
Shares Outstanding (mil) 282.17
Market Capitalization (mil) 172,813.91
Forward P/E 14.21
Dividend (Yield %) 2.00 ( 0.33 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.60 Mean rating from 30 analysts

KEY STATS

Revenue (mm, INR)
FY18
68,232
FY17
91,857
FY16
76,421
FY15
66,448
EPS (INR)
FY18
22.086
FY17
32.408
FY16
24.877
FY15
17.517
*Note: Units in Millions of Rupee
**Note: Units in Rupee

KEY RATIOS

Price to Earnings (TTM)
vs sector
14.21
32.90
Price to Sales (TTM)
vs sector
1.80
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
11.58
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Glenn Saldanha
Executive Chairman of the Board, Chief Executive Officer, Managing Director, Since 2011
Salary: Rs80,240,000.00
Bonus: --
V. Mani
President, Global Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Harish Kuber
Compliance Officer, Company Secretary, Since 2017
Salary: --
Bonus: --
Murali Neelakantan
Executive Director - Global General Counsel, Executive Director, Since 2017
Salary: --
Bonus: --
Cherylann Pinto
Director - Corporate Affairs, Since 2017
Salary: Rs27,000,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

B D S Marg
Chakala, Off Western Express Hig
Andheri (E),
MUMBAI     400099

Phone: +9122.40189999

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.

SPONSORED STORIES